

Benin

Population 2018

11 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	6.5 (4.2–9.3)	56 (37–81)
HIV-positive TB incidence	0.94 (0.61–1.4)	8.2 (5.3–12)
MDR/RR-TB incidence ^{oo}	0.1 (0.02–0.25)	0.89 (0.18–2.2)
HIV-negative TB mortality	1 (0.6–1.5)	8.8 (5.2–13)
HIV-positive TB mortality	0.32 (0.2–0.46)	2.8 (1.8–4)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	1.2% (0.21–3)
Previously treated cases	8.1% (4.9–12)

TB case notifications, 2018

Total new and relapse	4 003
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	98%
- % pulmonary	92%
- % bacteriologically confirmed ^{ooo}	89%
- % children aged 0-14 years	5%
- % women	32%
- % men	63%
Total cases notified	4 096

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	62% (43–95)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	21% (11–33)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	574	15%
- on antiretroviral therapy	539	94%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	31%
- Previously treated cases	100%
Laboratory-confirmed cases*	MDR/RR-TB: 27, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 24, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	25

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	87%	3 561
Previously treated cases, excluding relapse, registered in 2017	80%	98
HIV-positive TB cases registered in 2017	77%	549
MDR/RR-TB cases started on second-line treatment in 2016	82%	11
XDR-TB cases started on second-line treatment in 2016		0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	7%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	86% (79–94)

TB financing, 2019

National TB budget (US\$ millions)	3.6
Funding source: 7% domestic, 59% international, 34% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females
■ Males
 Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive
■ MDR/RR-TB
■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically